Minaris Regenerative Medicine Strengthens Global and Regional Leadership

Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership.

Minaris Regenerative Medicine, having facilities in the U.S., Germany, and Japan, will shift to a model of regional operational leadership on October 1, 2021. Under the new model, its three regional Chief Operating Officers (COOs) will collaborate on a Global Functional team to ensure alignment across the three regional companies. This shift is expected to allow for more strategic focus on regional operations, including both short-term projects and long-term capacity planning.

To successfully fulfill the regional and global operations leadership model, the following appointments have been made.

In Japan, Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager, Regenerative Medicine Business Sector, Showa Denko Materials Co., Ltd., in November 2020, will become President and Chief Executive Officer of Minaris Regenerative Medicine, Japan, effective August 1, 2021.

In the United States, Jo Anne Valentino, who has served as Vice President, Global Head of Quality since January 2019, following an extensive career in quality and operations management including at Novartis and Merck, will assume the role of Chief Operating Officer, United States, on October 1, 2021.

In Germany, Renate Sporrer, who joins Minaris Regenerative Medicine with fifteen years’ experience in quality and operations management, including at Roche, Polpharma Biologics, Novartis, and Sandoz GmbH, has been appointed Chief Operating Officer, Germany, effective July 1, 2021.

For Global Quality, Jacqueline Veivia-Panter, who joined Minaris Regenerative Medicine in October 2019 as Senior Director, Quality for its Allendale, New Jersey site, will succeed Jo Anne Valentino as Global Head, Quality effective October 1, 2021. Jacqueline has an extensive career in Quality leadership, and currently serves as Regulatory and Quality Advisory Board Chair for the Parenteral Drug Association (PDA). Jackie will maintain leadership of our Global Quality Leadership Team and will continue to drive forward the globalization of our Quality Management Systems.

“Congratulations to Hiroto, Jo Anne, Renate, and Jacqueline for their appointments into these critical regional and global roles,” said Kazuchika Furuishi, PhD, Corporate Officer, Showa Denko Materials Co., Ltd.; General Manager, Showa Denko Materials Regenerative Medicine Business Sector; and President and CEO, Minaris Regenerative Medicine, North America. “I am pleased to see effective promotion and strengthening for our executive, quality and operations roles, and I know our regional operations and global quality remain in good hands with these four seasoned pharmaceutical professionals in leadership positions.”

Brian Hanifin, who is currently in the role of Global Chief Operating Officer for Minaris Regenerative Medicine, has decided to leave the organization to pursue other opportunities effective September 30, 2021.

“Thank you, Brian, for your service to Minaris Regenerative Medicine over the past three years during a period of significant expansion and harmonization of our operations,” said Dr. Furuishi.

Minaris Regenerative Medicine consists of Minaris Regenerative Medicine, LLC, based in the United States, Minaris Regenerative Medicine GmbH, based in Germany, and its Yokohama, Japan site as part of Showa Denko Materials Co., Ltd., which will assume the name Minaris Regenerative Medicine Co., Ltd. effective August 1, 2021.